HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...
Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp's first time to launch an innovative biotech company. He was also one of ...
ATTR-CM is a rare, underdiagnosed contributor to heart failure. There is no cure, but newer treatments can slow the progression of the disease. Early detection and treatment are key to a better ...
Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...
The type of ATTR you have and how early it was diagnosed are two factors that can affect the prognosis of your disease.
A new blood test from Quest Diagnostics has Alzheimer's experts concerned. The Quest AD-Detect test, which consumers can now purchase from home without visiting a doctor first, measures amyloid-beta ...
Acumen Pharmaceuticals is developing ACU193 as the first clinical-stage therapeutic to selectively target toxic soluble amyloid-β oligomers (AβOs), which are an early and persistent driver of ...
MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback